Driving the Best Science to Meet Global Health Challenge s

 
bacterium ulcerans infection in Akonolinga, Cameroon
Y .K . Mueller, P . Nkemenang, M . Bastard, G . Ehounou, B . Rusch, 
E . Comte, E . Njih Tabah, L . Toutous Trellu, J .-F . Etard (Geneva, 
CH; Yaounde, CM; Paris, FR) 
O.3.2.18.004 
Antibody-mediated neutralisation of the exotoxin 
11 .15
 
mycolactone prevents cells from undergoing apoptosis
J .-P . Dangy, N . Scherr, R . Bieri, P . Gersbach, K .-H . Altmann, 
G . Pluschke (Basel, Zurich, CH) 
O.3.2.18.005 
Sero-epidemiology of Buruli ulcer in the Offin river valley 
11 .30
 
of Ghana
K .A . Ampah, K . Röltgen, P . Asare, D .D .-G . Binnah, S . Aboagye, 
A . Ross, B . Nickel, D . Yeboah-Manu, G . Pluschke (Accra, GH; 
Basel, CH) 
O.3.2.18.006 
Parasitic skin diseases and dermatomycoses in rural 
11 .45
 
Amazonia are associated with poverty
A . Lütkepohl, M . Borborema, L . Ariza, H . Feldmeier (Berlin, DE; 
Fortaleza, Manaus, BR) 

24
SCIENTIFIC PROGRAMME 
Monday, 7 September 2015
10 .30 – 12 .00
 
Parallel Session 4.6.1. 
Kairo 1
 
(Health and social systems)
 
 Clinical challenges in global health and patient 
management in health facilities with limited 
resources 
 
Convener and Chair: Andreas Neumayr (Basel, CH) 
INV.4.6.1.001 
Challenges in diagnosis of fever in rural Asia
10 .30
 
Paul Newton (Ventiane, LA) 
O.4.6.1.002 
Development of guidance for the diagnostic management 
11 .00
 
of patients with neurological disorders in hospitals in 
Bandundu, Democratic Republic of the Congo, with a focus 
on not-to-miss infections of the central nervous system
E . Bottieau, D . Mukendi, K . Verdonck, C . Yansouni, 
T . Kayembe, S . Burza, A . Mpanya, J .-R . Kalo, B . Barbé, 
C . Schurmans, P . Büscher, R . Ravinetto, A . Winkler, J . Menten, 
H . van Loen, J . Jacobs, P . Lutumba, M . Boelaert, F . Chappuis 
(Antwerp, BE; Kinshasa, CD; Montreal, CA; London, GB; 
München, DE; Geneva, CH) 
O.4.6.1.003 
Bloodstream bacterial infection among outpatient children
11 .15
 
with acute febrile illness in north-eastern Tanzania 
C . Mahende, B . Ngasala, J . Lusingu, Z . Premji (Dar es Salaam, 
Tanga, TZ) 
O.4.6.1.004 
Application of the Luminex xTAG gastrointestinal 
11 .30
 
pathogen panel for the detection of gastrointestinal 
 pathogens in a rural African setting 
D . Eibach, R . Krumkamp, A . Hahn, N . Sarpong, Y . Adu-Sarkodie, 
A . Leva, J . Adlkofer, M . Panning, J . May, E . Tannich (Freiburg, 
Hamburg, Hamburg-Borstel-Lübeck, DE; Kumasi, GH) 
O.4.6.1.005 
Characterising the health facility infrastructure in 
11 .45
 
countries with endemic sleeping sickness for effective 
targeting of diagnostic resources
P .R . Bessell, S . Biéler, J .M . Ndung‘u (Edinburgh, GB; Geneva, CH) 
 

25
SCIENTIFIC PROGRAMME 
Monday, 7 September 2015
Scientific Pr
og
ramme
10 .30 – 12 .00
 
Poster Speed Talks 1 
Kairo 2 
 
Diseases of poverty speed talks 
 
Chair: Marcel Tanner (Basel, CH) 
PST1.001 
pVLP: a new DNA vaccine strategy for HIV
10 .30
 
 A .R . Calazans, R . Lindsay, G . Morrow, C . Parks (Rio de Janeiro, 
BR; Brooklyn, US) 
PST1.002 
What determines the ANRS 12174 trial mothers’ breast-
10 .35
 
feeding behavior?
E .N . Some, I .M . Engebretsen, N . Nagot, N . Meda, P . Van De 
Perre, T . Tylleskär (Bobo Dioulasso, Ouagadougou, BF; Bergen, 
NO; Montpellier, FR) 
PST1.004 
Persistence of real-time PCR positivity after successful 
10 .40
 
treatment of Plasmodium falciparum malaria: implications 
for estimates of parasite prevalence and density
M . Vafa Homann, S .N . Emami, V . Yman, K . Sondén, A . Färnert 
(Stockholm, SE) 
PST1.005 
Polymer and lipid based drug delivery strategies for 
10 .45
 
malaria treatment
L . du Plessis, A . Kotze (Potchefstroom, ZA) 
PST1.006 
Salynomycin and other ionophores as antimalarials and 
10 .50
 
transmission blocking agents
S . D‘Alessandro, S . Parapini, N . Dahiya, S .M . Abay, A . Habluetzel, 
K . Dechering, K . Koolen, R .W . Sauerwein, N . Basilico, 
D . Taramelli (Camerino, Milano, IT; Nijmegen GA, NL) 
PST1.007 
Mutations in K13, Pfcrt and Pfmdr1 genes and efficacy 
10 .55
 
of artemether- lumefantrine in relation to treatment 
outcomes in Kenyan children with uncomplicated 
falciparum malaria
L .A .I . Olubayo, D .W . Juma, A .A . Omondi, B .M . Andagalu, 
H .M . Akala, B . Ogutu, E . Kamau (Kisumu, KE) 
PST1.009 
Diagnostic value of three interferon-gamma release assays 
11 .00
 
for paediatric tuberculosis in a high HIV/TB -prevalence 
setting in South-West Tanzania
I . Kroidl, L . Podola, P . Clowes, A . Rachow, K . Reither, 
E . Saathoff, C . Geldmacher, M . Kalomo, E .N . Ntinginya, 
L . Maboko, A . Kroidl, T . Löscher, M . Hoelscher (Mbeya, TZ; 
Munich, DE; Basel, CH) 
PST1.010 
Diagnosing latent tuberculosis with interferon-gamma 
11 .05
 
release assays in patients with concurrent malaria 
infection in Tanzania
C .H . Drabe, N . Nyagonde, F . Francis, M .V . Rose, M . Helleberg, 
O .P . Theilgaard, J . Asbjørn, B . Amos, M .M . Lemnge, 
I .C . Bygbjerg, M . Ruhwald, P . Ravn, L .S . Vestergaard 
(Copenhagen, DK; Muheza, Tanga, TZ) 

26
SCIENTIFIC PROGRAMME 
Monday, 7 September 2015
PST1.011 
Safety of second-line antituberculosis agents in the context
11 .10
 
of multi-drug resistant tuberculosis therapy in Kinshasa: a 
pilot cohort study
Y . Lula, A . Engo, H . Muhindo, G . Nsimba, J . Mbo, R . Mulongo, 
S . Bisuta, G . Bakaswa, P . Lutumba, J .-P . Van geertruyden, 
G . Tona (Kinshasa, CD; Antwerp, BE) 
PST1.012 
Immune reconstitution inflammatory syndrome associated 
11 .15
 
with dermatophytoses in two HIV-1 positive patients in 
rural Tanzania
H . Mapesi, A . Ramirez, M . Battegay, H . Furrer, M . Tanner, 
C . Hatz, E . Letang (Ifakara, TZ; Palma de Mallorca, ES; Basel, 
Berne, CH) 
PST1.013 
Malaria policies versus practices, a reality check from 
11 .20
 
Kinshasa, the capital of the Democratic Republic of Congo
H .M . Mavoko, G . Llombe, R .I . da Luz, A . Kutekemeni, J .-P . Van 
Geertruyden, P . Lutumba (Kinshasa, CD; Antwerp, Kinshasa, BE) 
PST1.014 
Impact of malaria rapid diagnostic tests on patients‘ 
11 .25
 
subsequent treatment-seeking, costs and health outcomes: 
results from the ACT Consortium
H . Hopkins, P . West, S . Yeung, C .I . Chandler (London, GB) 
10 .30 – 12 .00
 
Parallel Session 3.3.1.  
Samarkand
 
(Disease systems) 
 
 The globalization of Chagas diseases: an emerging 
disease in Europe 
 
Convener and Chair: Joaquim Gascon (Barcelona, ES)  
 
Chair: Fabian Gusovsky (Andover, US) 
INV.3.3.1.001 
Chagas disease: the natural history of the disease
10 .30
 
Yves Jackson (Geneva, CH) 
INV.3.3.1.002 
Chronic Chagas Disease: To treat or not to treat?
10 .45
 
M .J . Pinazo (Barcelona, ES) 
INV.3.3.1.003 
Chagas disease in Europe: the challenges to face an 
11 .00
 
emerging infection
Andrea Angheben (Negrar, IT) 
INV.3.3.1.004 
Main challenges and potential strategies related with 
11 .15
 
R&D needs
Isabela Ribeiro (Geneva, CH) 
11 .30
 Discussion 

27
SCIENTIFIC PROGRAMME 
Monday, 7 September 2015
Scientific Pr
og
ramme
12 .00 – 13 .30
 
Poster Session I 
Hall 4.1 
 
(PS1.001 – PS1.358.LB)
 
Please refer to pages 122 – 155 for details
12 .15 – 13 .15
 
Satellite Symposium 
Sydney
 
Co-infections: its impact on neglected tropical 
 diseases 
 
For further details please refer to page 222
12 .15 – 13 .15
 
Satellite Symposium 
Singapore
 
 On the road to malaria elimination: where we have 
come from and what challenges lie ahead? 
 
For further details please refer to page 222 
13 .30 – 15 .00
 
Society Session 2 
San Francisco 
 
Royal Society of Tropical Medicine and Hygiene 
(RSTMH): the key contributions of disease mapping 
to global health 
 
 Chair: Gerri McHugh (London, GB)  
Chair: Catherine Moyes (Oxford, GB) 
SS2.001 
Spatial predictions of prevalence and access-to-care as a 
13 .30
 
basis for modeling impact of malaria interventions
Peter Pemberton-Ross (Basel, CH) 
SS2.002 
Mapping the future global distribution of risk for dengue
14 .00
 
Jane Messina (Oxford, GB) 
SS2.003 
The use of neglected tropical disease maps to inform 
14 .30
 
policy and programming
Rachel Pullan (London, GB) 

28
SCIENTIFIC PROGRAMME 
Monday, 7 September 2015
13 .30 – 15 .00
 
Parallel Session 3.2.11. 
Sydney
 
(Disease systems) 
 
Evaluating therapeutic interventions against Ebola: 
challenges and lessons learned 
 
Convener: Johan van Griensven (Antwerp, BE) 
 
Chair: Line Matthiessen (Brussels, BE)  
 
Chair: David Wood (Geneva, CH) 
INV.3.2.11.001 
Introduction
13 .30
 
Line Matthiessen (Brussels, BE)  
 
David Wood (Geneva, CH) 
INV.3.2.11.002 
The Ebola field reality for conducting clinical trials
13 .35
 
A . Antierens (Brussels, BE) 
INV.3.2.11.003 
Ethics of clinical trials in epidemic disasters
13 .45
 
Philippe Calain (Geneva, CH) 
INV.3.2.11.004 
Emergency evaluation of convalescent plasma for Ebola 
13 .55
 
virus disease in Guinea
J . van Griensven (Antwerp, BE) 
INV.3.2.11.005 
Trials of antivirals – ISARIC experience
14 .10
 
Peter Horby (Oxford, GB) 
INV.3.2.11.006 
Favipiravir in patients with Ebola virus disease
14 .25
 
D .J . Malvy (Bordeaux, FR) 
14 .40
 
Panel discussion – challenges and lessons  
learned 
13 .30 – 15 .00
 
Parallel Session 3.1.6. 
Singapore
 
(Disease systems) 
 
Answering key questions on malaria drug delivery – 
the importance of diagnostics 
 
Convener and Chair: Heidi Hopkins (London, GB) 
INV.3.1.6.001 
Improving malaria treatment and control through 
13 .30
 
enhanced diagnostic practice
David Schellenberg (London, GB) 
O.3.1.6.002 
Impact of malaria rapid diagnostic tests on patient care: 
14 .00
 
results from the ACT consortium
K . Bruxvoort, B . Leurent, H . Hopkins (London, GB) 
O.3.1.6.003 
Effects of introducing malaria rapid diagnostic tests in 
14 .15
 
drug shops: findings from the evaluation of a cluster 
randomised trial in Uganda
A .K . Mbonye, P . Magnussen, E . Hutchinson, K .S . Hansen, 
S . Lal, S .E . Clarke (Kampala, UG; Copenhagen, DK; London, 
GB) 
O.3.1.6.004 
Improving appropriate use of quality-assured RDTs in the
14 .30
 
private sector: baseline and midterm evaluation results 
from Uganda 
R . Mugerwa (Kampala, UG) 
O.3.1.6.005 
Factors impacting malaria rapid diagnostic test performance
14 .45
 
N . Zwingerman, M . Cancino, S . Ferro (Toronto, CA) 

29
SCIENTIFIC PROGRAMME 
Monday, 7 September 2015
Scientific Pr
og
ramme
13 .30 – 15 .00
 
Parallel Session 3.1.2. 
Montreal
 
(Disease systems) 
 
Implementation research for malaria elimination. 
Emerging results from Malaria Eradication Scientific 
Alliance (MESA) – supported projects 
 
 Convener and Chair: Regina Rabinovich (Barcelona, ES; 
Boston, US) 
INV.3.1.2.001 
Efficacy and safety of high-dose ivermectin for reducing 
13 .30
 
malaria transmission: a dose finding study
M .R . Smit (Liverpool, GB) 
INV.3.1.2.002 
Mopping up and getting to zero: mapping residual malaria
13 .45
 
transmission for targeted response in urban Lusaka, Zambia
Daniel Bridges (Lusaka, ZM) 
INV.3.1.2.003 
Active detection of infection for malaria elimination in 
14 .00
 
South Cotabato, Mindanao, The Philippines: performance 
of LAMP for screening people in their home villages
CJ . Sutherland (London, GB) 
INV.3.1.2.004 
Targeting pregnant women to measure malaria transmission
14 .15
 
 A .M . Fonseca, E . Macete, R . González, C . Jairoce, J . Hegewisch, 
M . Rupérez, L . Quintó, P . Cisteró, A . Vala, A . Jiménez, 
A . Nhacolo, C . Chitnis, E . Sevene, C . Menéndez, A . Mayor 
(Barcelona, ES; Porto, PT; Manhiça, MZ; New Delhi, IN) 
O.3.1.2.005.LB 
Malaria and the mobile and migrant population in
14 .30
 
Cambodia: a population movement framework to inform 
strategies for malaria control and elimination
S . Canavati, P . Guyant, C . Nguon, P . Ly, M . Whittaker, A . Roca-
Feltrer, S . Yeung (Asia, Bangkok, TH; London, GB; Phnom 
Penh, KH; Brisbane, AU) 

30
SCIENTIFIC PROGRAMME 
Monday, 7 September 2015
13 .30 – 15 .00
 
Parallel Session 3.3.4. 
Delhi
 
(Disease systems) 
 
Global faces of challenges with diabetes and 
hypertension 
 
Convener and Chair: Nino Künzli (Basel, CH)  
 
Chair: Nerges Furdoon Mistry (Pune, IN) 
O.3.3.4.001 
A community based model for care and control of type 2 
13 .30
 
diabetes in rural Western India
N .F . Mistry, B . Mote, L . Garda, R . Dope, A . Bopardikar (Pune, IN) 
O.3.3.4.002 
Environmental tobacco smoke exposure and diabetes in 
13 .45
 
adult never-smokers
I .C . Eze, E . Schaffner, E . Zemp, A . von Eckardstein, A . Turk, 
R . Bettschart, C . Schindler, N . Probst-Hensch (Aarau, Basel, 
Wald-Faltigberg, Zurich, CH) 
O.3.3.4.003 
Are we treating the right people- are we treating the 
14 .00
 
people right? Analysis of patients attending the Diabetes 
Clinic at Kamuzu Central Hospital, Lilongwe, Malawi
A .T . Yassin, P . Kanyengambeta, C . Zinyemba, L . Gondwe, 
M . Zeier, Y . Mlombe, F . Neuhann (Heidelberg, DE; Lilongwe, 
MW) 
O.3.3.4.004 
Complications of diabetes and hypertension at a referral 
14 .15
 
hospital in Zimbabwe
M . Mutowo, P . Lorgelly, J .C . Mangwiro, A . Renzaho, A . Owen 
(Melbourne, Sydney, AU; Harare, ZW) 
O.3.3.4.005 
Prevalence of hypertension and associated risk factors 
14 .30
 
among diabetes patients in urban Dar es Salaam, 
Tanzania: a case for integrated care
J .J . Hella, B . Doulla, F .A . Mhimbira, N .B . Blanco, Z . Ngoma, 
A . Swai, K . Ramaiya, L . Fenner (Dar es Salaam, TZ; Basel, CH) 
O.3.3.4.006 
Tackling NCDs and risk factors in Kyrgyzstan: the impact 
14 .45
 
of community action for health in Kyrgyzstan
T . Djamangulova, R . Aidaraliev, G . Siupsinskas (Bishkek, KG; 
Berne, CH) 

31
SCIENTIFIC PROGRAMME 
Monday, 7 September 2015
Scientific Pr
og
ramme
13 .30 – 15 .00
 
Parallel Session 4.2.2. 
Boston 1
 
(Health and social systems) 
 
Determinants of health and help seeking behavior 
 
Convener and Chair: Carol Vlassoff (Ottawa, CA) 
INV.4.2.2.001 
Towards a comprehensive framework for community study 
13 .30
 
of vaccine acceptance
M .G . Weiss, A . Kudale (Basel, CH; Pune, IN) 
O.4.2.2.002 
Cultural beliefs are not the key determinants of 
14 .00
 
treatment-seeking behaviour: lessons from ethnographic 
fieldwork in regions of Benin‘s Ouémé River valley endemic 
for Buruli ulcer
M . Boyer (Tampa, US) 
O.4.2.2.003 
Healthcare-seeking behaviour and experiences of rehabili-
14 .15
 
tation among disabled youth in Ghana
S . Gregorius (Liverpool, GB) 
O.4.2.2.004 
Predicting non-communicable disease in Canada based on 
14 .30
 
behavioral risk factors and social determinants of health
Y . Jia, K . Mukhopadhyay, P .J . Thomassin (Montreal, CA) 
O.4.2.2.005 
Measuring the status of household water, sanitation and
14 .45
 
hygiene behaviours in rural Bangladesh: an application of 
qualitative information system
T . Akter, F .T . Jhohura, T .R . Chowdhury, F . Akter, S .K . Mistry, 
M . Rahman (Dhaka, BD) 
13 .30 – 15 .00
 
Parallel Session 4.3.4. 
Boston 2
 
(Health and social systems) 
 
The good, the bad and the ugly of global targets. 
 
Will the SDGs be different? 
 
Convener and Chair: Xavier Bosch-Capblanch (Basel, CH) 
INV.4.3.4.001 
From Alma Ata to sustainable development goals
13 .30
 
X . Bosch-Capblanch (Basel, CH) 
INV.4.3.4.002 
What did the MDGs do for global health? Will the SDGs 
13 .40
 
do more?
Jan Vandemoortele (Bruges, BE) 
INV.4.3.4.003 
Unmet Agenda in post-MDG era and role of the Global 
14 .00
 
Fund for SDGs
O . Kunii (Geneva, CH) 
INV.4.3.4.004 
GAVI contribution to the MDGs and plans for the SDGs
14 .15
 
A . Bchir (Geneva, CH) 
14 .30
 Discussion 

32
SCIENTIFIC PROGRAMME 
Monday, 7 September 2015
13 .30 – 15 .00
 
Parallel Session 5.3.2. 
Shanghai 1
 
(From research to implementation) 
 
The reality of open source drug discovery: a move 
towards multilateral collaborations 
 
Convener and Chair: Graeme Bilbe (Geneva, CH)  
 
Chair: Matthew Todd (Sydney, AU) 
13 .30
 Introduction 
INV.5.3.2.001 
Re-engineering how we innovate for public health
13 .35
 
 P .L . Olliaro, M . Todd, R . Kiddell-Monroe, M . Basey, 
A . Greenberg, M . Balasegaram, E . Torreele (Geneva, CH; 
Oxford, GB; Sydney, AU; New York, Washington, US) 
INV.5.3.2.002 
The NTD Drug Discovery Booster: an innovative multiparty
13 .50
 
collaboration on early drug discovery
C .E . Mowbray (Geneva, CH) 
O.5.3.2.003 
MMV malaria box and pathogen box projects: the applica-
14 .05
 
tion of open science
P .A . Willis, T .N .C . Wells, W .C . Van Voorhis, T . Spangenberg 
(Geneva, CH) 
INV.5.3.2.004 
The open source drug discovery project
14 .20
 
Samir Brahmachari (New Delhi, IN) 
INV.5.3.2.005 
Creating a global community for clinical drug repurposing
14 .35
 
and development
L .V . Sacks (Silver Spring, US) 
14 .50
 Discussion 
13 .30 – 15 .00
 
Tropical Medicine & International 
Shanghai 2
 
Health (TMIH) Workshop 1 
 
Writing for real people: how to make your papers 
attractive, clear and popular 
Organizer: Susanne Groener (London, GB) 

33
SCIENTIFIC PROGRAMME 
Monday, 7 September 2015
Scientific Pr
og
ramme
13 .30 – 15 .00
 
Parallel Session 4.6.2. 
Kairo 1 
 
(Health and social systems)
 
Medical and public health education in Africa 
 
Convener and Chair: Axel Hoffmann (Basel, CH) 
INV.4.6.2.001 
Accelerating excellence and leadership in African health 
13 .30
 research
Fred Binka (Accra, GH) 
INV.4.6.2.002 
Global Collaboration: An essential element for public 
13 .45
 
health and medical education in Africa
Kevin Marsh (Oxford, GB) 
O.4.6.2.003 
What are the mutual benefits for universities participating
14 .00